Furthermore, although trastuzumab therapy has been a milestone in the treatment of HER2+ BC, in recent years the number of approved anti-HER2 therapeutic agents has been significantly expanded leading to improved outcomes for patients with HER2+ and even HER2-low BC [34]. Here, ERBB2 is linked to breast cancer.